OpenAI has launched Rosalind Biodefense, a program giving vetted developers access to GPT-Rosalind, its frontier reasoning model built for life sciences research. The company also expanded trusted access for select U.S. government and allied partners working on public health and biodefense missions.
OpenAI sponsors model access and provides launch support to trusted developers building biodefense applications. The initial developer cohort includes Fourth Eon, SecureDNA, SecureBio Detection, and ProEquip.
Government partners include Lawrence Livermore and Johns Hopkins Applied Physics Laboratory, plus CEPI for vaccine work. Use cases span epidemiological modeling, early detection, screening, and medical countermeasure development.
OpenAI first treated July 2025's ChatGPT agent as High Capability in biology under its Preparedness Framework. The new program reflects an emerging playbook for dual-use AI: powerful enough to be dangerous, distributed only to defenders. If gated access works here, it becomes the template for every dangerous capability that follows.